Medicines Patent Pool, an organization supported by the U.N., announced on Thursday that over two dozen generic drug makers will soon begin producing Merck's COVID-19 pill to make the treatment more accessible in developing countries.
The organization said that 27 generic drug makers would produce the pill for 105 developing countries. Specifically, agreements the companies signed allow them to make both molnupiravir's raw ingredients as well as the final product.
Molnupiravir is the COVID-19 treatment developed by Merck and Ridgeback Therapeutics. For patients with early signs of COVID-19, the pill is believed to cut the hospitalization rates in half.
Johnson & Johnson's booster shot provides high levels of protection against the omicron variant of Covid-19, according to data from a trial of healthcare workers in South Africa released Thursday.
Preliminary results from the Sisonke study, which have not been peer-reviewed, found that for people who had received one vaccine dose, the booster improved protection against hospitalization to 85 percent from 63 percent.
If confirmed in follow-up research and if the diagnostics industry can pivot quickly enough, findings from a South African study could make COVID-19 testing a lot easier for patients and healthcare workers, as the SARS-CoV-2 Omicron variant becomes the dominant source of infection.
/cloudfront-us-east-2.images.arcpublishing.com/reuters/W7CJRN6DARIQTDCSJKEMAVAT6E.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/I5J43TTBBRLXZL3KDDZ36NIUXA.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/LBU346OSLVIU7KTSC7EAS7DRIA.jpg)
